Post-earnings recap
Reported
Tue, May 8, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which contributed to a 6.51% drop in the stock price. The lack of revenue details and future guidance has left investors cautious about the company's near-term prospects. Overall, the results indicate challenges that may impact investor confidence moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -25.32% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, reflecting concerns about current performance. They did not offer any future guidance, leaving investors uncertain.
Management did not provide specific guidance for the upcoming quarters.
The company acknowledged challenges in meeting market expectations.